



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 62648

**Title:** Molecular-targeted therapy toward precision medicine for gastrointestinal cancer:  
Current progress and challenges

**Reviewer's code:** 03093768

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor, Doctor, Surgeon, Surgical Oncologist

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-01-14

**Reviewer chosen by:** Jin-Lei Wang

**Reviewer accepted review:** 2021-01-14 11:34

**Reviewer performed review:** 2021-01-17 10:42

**Review time:** 2 Days and 23 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

The content of the review is very comprehensive, which summarizes the advancement of precision medicine in GI cancer. The first part named "targeting the RAS / Raf / MEK pathway" seems not proper, why not named it "targeting EGFR"? Maybe this title is more consistent with the following figures and tables. I believe it is necessary to properly introduce the relationship between RAS / Raf / MEK pathway and EGFR. It seems that the writing style of this part is not consistent with that of the following parts.



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 62648

**Title:** Molecular-targeted therapy toward precision medicine for gastrointestinal cancer:  
Current progress and challenges

**Reviewer's code:** 03080579

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor, Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-01-14

**Reviewer chosen by:** Jin-Lei Wang

**Reviewer accepted review:** 2021-01-16 01:19

**Reviewer performed review:** 2021-01-28 04:19

**Review time:** 12 Days and 2 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

The manuscript clarifies the current evidence for targeted therapies in GI cancer by evaluating the latest data regarding anti-EGFR, HER2, VEGF, PI3K/AKT, TGF- $\beta$ , MET, WNT, PARP and immunotherapies. And Targeting these molecules will improve the outcomes of patients with GI cancer. The review concept is clear. And the manuscript is well and concisely written. However, English editing is required.



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 62648

**Title:** Molecular-targeted therapy toward precision medicine for gastrointestinal cancer:  
Current progress and challenges

**Reviewer's code:** 03093768

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor, Doctor, Surgeon, Surgical Oncologist

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-01-14

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2021-03-09 10:32

**Reviewer performed review:** 2021-03-09 12:01

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**https://**[www.wjgnet.com](https://www.wjgnet.com)

Thank you for your work in revising your manuscript. I think this manuscript is good enough to be accepted for publication.